Pharmacogenetics in HIV Treatment: Clinical Applications, Limitations, and Ethical Considerations
Overview
This paper examines pharmacogenetics in the context of HIV treatment, focusing on genetic testing applications such as CYP2C19 isozyme variations in clopidogrel therapy and HLA-B*5701 allele testing for abacavir sensitivity. The paper analyzes clinical decision-making regarding drug prescription, identifies key limitations in pharmacogenomics testing, and addresses ethical concerns associated with genetic testing in medical practice.
What this coursework covers
- Introduction to pharmacogenetics and HIV treatment approaches
- Genetic testing in antiplatelet therapy and CYP2C19 isozyme variations
- HLA-B*5701 allele testing and abacavir prescription decision-making
- Limitations of pharmacogenomics testing including gene identification challenges and drug metabolism mutations
- Ethical concerns in pharmacogenomics testing application
Preview
Pharmacogenetics
Student’s Name
Institution Affiliation
Professor
Course
Date
Pharmacogenetics
The treatment of HIV has been evolving over the years and there has been a tremendous effort to ensure that patients do not suffer throughout the process. The study of HIV has largely taken two angles, the search for the best drug and methods to reduce the virus load in patients and the search for drugs that reduce the type and number of reactions among patients. Strides have been made in both efforts although there are biological and ethical concerns in the endeavor. As more drugs that reduce the virus load in patients are unveiled, questions are being asked on how the patients can be protected from adverse allergic reactions and some of the parameters include the type of reaction, the healing time, and the number of reactions a patient can have after one medication. Some medicines are mandatory in the reduction of the viral load and sometimes the patients are forced to ingest anti-allergens after they consume the medication. They help reduce the adverse reactions while the main medication attack HIV.
Genetic testing in antiplatelet therapy (clopidogrel)
CYP2C19 isozyme genetic variations are partly responsible for clopidogrel impaired conversion to its active metabolite. Genetic testing helps in the identification of the CYP2C19 isozyme and prevents an array of atherothrombotic diseases that may lead to the patient’s death. An impaired clopidogrel efficacy due to the existence of CYP2C19 isozyme increases the risk of adverse cardiovascular attacks and genetic testing helps in its identification thus preserving the patient’s life.